Shingrix is an adjuvanted recombinant zoster vaccine, consisting of the varicella-zoster virus glycoprotein E antigen and the AS01B adjuvant system, a proprietary adjuvant containing QS-21 and MPL with liposomes.
Shingrix is a vaccine for the prevention of shingles (herpes zoster) in adults 50 years and older.
Shingrix is not used to prevent primary varicella infection (chickenpox).
Shingrix is a suspension for intramuscular injection only. It is supplied in 2 vials that must be combined prior to administration.
Two doses are necessary to provide strong protection, up to 90%, the first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
Due to the limited supply, the CDC has stated: If more than 6 months have elapsed since the 1st Shingrix dose, administer the 2nd dose as soon as possible. Do not restart the Shingrix vaccine series.
Find a pharmacy or doctor near you to start your Shingrix vaccine series
July 9, 2019, GSK Herpes Zoster Vaccine Shingrix reduced the incidence of herpes zoster in autologous stem cell transplant recipients
May 22, 2019, China’s National Medical Product Administration (NMPA) announced the ‘conditional approval’ for Shingrix.
Shingrix' Clinical Trial numbers: NCT00434577, NCT00492648, NCT00802464, NCT00920218, NCT01086449, NCT01165177, NCT01165203, NCT01165229, NCT01295320, NCT01751165, NCT01777321, NCT01827839, NCT01954251 and NCT02075515